Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 51 - 100 av 510 resultater
Tid
Selskap
Tittel
Sektor
Kategori
08 Aug 2024
07:00 CEST
SANOFI
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
20103015 Pharmaceuticals
Other subject
08 Aug 2024
07:00 CEST
SANOFI
Communiqué : Le traitement d’induction par Sarclisa a démontré une amélioration significative de la survie sans progression chez les patients atteints d’un myélome multiple nouvellement diagnostiqué et éligibles à une transplantation
20103015 Pharmaceuticals
Other subject
25 Jul 2024
16:56 CEST
SANOFI
Communiqué de presse : Mise en ligne du rapport financier semestriel 2024 de Sanofi
20103015 Pharmaceuticals
Other subject
25 Jul 2024
16:56 CEST
SANOFI
Press Release: Online availability of Sanofi’s half-year financial report for 2024
20103015 Pharmaceuticals
Other subject
25 Jul 2024
07:30 CEST
SANOFI
Communiqué de presse : Forte performance au deuxième trimestre soutenue par une croissance des ventes de 10% - Perspectives 2024 relevées
20103015 Pharmaceuticals
Other subject
25 Jul 2024
07:30 CEST
SANOFI
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
20103015 Pharmaceuticals
Other subject
22 Jul 2024
22:05 CEST
SANOFI
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Juin 2024
20103015 Pharmaceuticals
Share history
22 Jul 2024
22:05 CEST
SANOFI
Sanofi: Information concerning the total number of voting rights and shares – June 2024
20103015 Pharmaceuticals
Share history
17 Jul 2024
23:27 CEST
SANOFI
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
20103015 Pharmaceuticals
Other subject
17 Jul 2024
23:27 CEST
SANOFI
Communiqué de presse : Le NEJM publie les données de phase III de l’étude XTEND-Kids montrant qu’ALTUVIIIO a le potentiel de transformer la prise en charge thérapeutique des enfants atteints d’hémophilie A sévère
20103015 Pharmaceuticals
Other subject
03 Jul 2024
07:00 CEST
SANOFI
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
20103015 Pharmaceuticals
Other subject
03 Jul 2024
07:00 CEST
SANOFI
Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenne
20103015 Pharmaceuticals
Other subject
26 Jun 2024
23:30 CEST
SANOFI
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
20103015 Pharmaceuticals
Other subject
26 Jun 2024
23:30 CEST
SANOFI
Communiqué de presse : Publication dans le NEJM des données positives de phase III du Dupixent dans le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 12 mois à 11 ans
20103015 Pharmaceuticals
Other subject
25 Jun 2024
19:32 CEST
SANOFI
Press Release: Availability of the Q2 2024 Aide-mémoire
20103015 Pharmaceuticals
Other subject
25 Jun 2024
19:32 CEST
SANOFI
Communiqué de presse : Mise en ligne du document « Aide-mémoire Q2 2024 »
20103015 Pharmaceuticals
Other subject
21 Jun 2024
09:30 CEST
SANOFI
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
20103015 Pharmaceuticals
Other subject
21 Jun 2024
09:30 CEST
SANOFI
Communiqué de presse : Audrey Duval Derveloy nommée Directrice Affaires Corporate Groupe, membre du Comité exécutif de Sanofi
20103015 Pharmaceuticals
Other subject
21 Jun 2024
07:00 CEST
SANOFI
Communiqué de presse : ISTH : De nouvelles données sur ALTUVIIIO et le fitusiran confortent le leadership de Sanofi dans le traitement de l’hémophilie
20103015 Pharmaceuticals
Other subject
21 Jun 2024
07:00 CEST
SANOFI
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
20103015 Pharmaceuticals
Other subject
20 Jun 2024
14:00 CEST
SANOFI
Communiqué de presse : Sanofi et Biovac pionniers de la production de vaccins contre la polio en Afrique
20103015 Pharmaceuticals
Other subject
20 Jun 2024
14:00 CEST
SANOFI
Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
20103015 Pharmaceuticals
Other subject
12 Jun 2024
20:19 CEST
SANOFI
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2024
20103015 Pharmaceuticals
Share history
12 Jun 2024
20:19 CEST
SANOFI
Sanofi: Information concerning the total number of voting rights and shares – May 2024
20103015 Pharmaceuticals
Share history
03 Jun 2024
22:15 CEST
SANOFI
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
20103015 Pharmaceuticals
Other subject
03 Jun 2024
22:15 CEST
SANOFI
Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […]
20103015 Pharmaceuticals
Other subject
31 May 2024
12:00 CEST
SANOFI
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
20103015 Pharmaceuticals
Other subject
31 May 2024
12:00 CEST
SANOFI
Communiqué de presse : Sanofi lance son plan mondial 2024 d’actionnariat salarié
20103015 Pharmaceuticals
Other subject
31 May 2024
07:05 CEST
SANOFI
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
20103015 Pharmaceuticals
Other subject
31 May 2024
07:05 CEST
SANOFI
Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO
20103015 Pharmaceuticals
Other subject
31 May 2024
07:00 CEST
SANOFI
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
20103015 Pharmaceuticals
Other subject
31 May 2024
07:00 CEST
SANOFI
Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2
20103015 Pharmaceuticals
Other subject
30 May 2024
15:01 CEST
SANOFI
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
20103015 Pharmaceuticals
Other subject
30 May 2024
15:01 CEST
SANOFI
Communiqué de presse : Sanofi finalise l’acquisition d’Inhibrx, Inc.
20103015 Pharmaceuticals
Other subject
27 May 2024
07:00 CEST
SANOFI
Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantation
20103015 Pharmaceuticals
Other subject
27 May 2024
07:00 CEST
SANOFI
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
20103015 Pharmaceuticals
Other subject
21 May 2024
07:30 CEST
SANOFI
Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA
20103015 Pharmaceuticals
Other subject
21 May 2024
07:30 CEST
SANOFI
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
20103015 Pharmaceuticals
Other subject
20 May 2024
22:54 CEST
SANOFI
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2024
20103015 Pharmaceuticals
Share history
20 May 2024
22:54 CEST
SANOFI
Sanofi: Information concerning the total number of voting rights and shares - April 2024
20103015 Pharmaceuticals
Share history
20 May 2024
20:15 CEST
SANOFI
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
20103015 Pharmaceuticals
Other subject
20 May 2024
20:15 CEST
SANOFI
Communiqué de presse : Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCO
20103015 Pharmaceuticals
Other subject
13 May 2024
07:00 CEST
SANOFI
Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty
20103015 Pharmaceuticals
Other subject
13 May 2024
07:00 CEST
SANOFI
Communiqué de presse : Sanofi investit plus d’un milliard d’euros supplémentaires dans la production de médicaments en France, en plus des 2,5 milliards d’euros déjà engagés dans de grands projets de souveraineté sanitaire
20103015 Pharmaceuticals
Other subject
10 May 2024
08:00 CEST
SANOFI
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
20103015 Pharmaceuticals
Other subject
10 May 2024
08:00 CEST
SANOFI
Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19
20103015 Pharmaceuticals
Other subject
02 May 2024
07:00 CEST
SANOFI
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
20103015 Pharmaceuticals
Other subject
02 May 2024
07:00 CEST
SANOFI
Communiqué de presse : Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS
20103015 Pharmaceuticals
Other subject
30 Apr 2024
18:00 CEST
SANOFI
Press Release: Annual General Meeting of April 30, 2024
20103015 Pharmaceuticals
Other subject
30 Apr 2024
18:00 CEST
SANOFI
Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024
20103015 Pharmaceuticals
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva